Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACURA PHARMACEUTICALS, INCACUR · Entity 69367 | 10% owner | June 09, 2021 | June 28, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACURA PHARMACEUTICALS, INC
Report date June 09, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Abuse Deterrent Pharma, LLC | 42,984,375 |
Reported balance
After 2021-06-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-06-09 · Conversion · Acquired 42,984,375 · Balance 42,984,375 F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.16 | IndirectBy Abuse Deterrent Parma, LLC | 0 |
Reported balance
After 2021-06-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-06-09 · Conversion · Disposed Not disclosed · Balance 0 F2: On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock. F3: This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023. F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 8,912,655 |
Reported balance
Holding disclosure · report date 2021-06-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 8,912,655 |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.53 · Expires 2022-07-23 | Direct | 1,782,531 |
Reported balance
Holding disclosure · report date 2021-06-09 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,782,531 |
| Warrant to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.01 · Expires 2024-06-28 | IndirectBy Abuse Deterrent Parma, LLC | 10,000,000 |
Reported balance
Holding disclosure · report date 2021-06-09 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 10,000,000 F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person is the manager and a member of AD Pharma. The Reporting Person hereby disclaims beneficial ownership of the securities, except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F2: On the conversion date, $6,000,000 of principal and $877,500 of interest under the note was converted into the Issuer's common stock. For each $0.16 converted, AD Pharma received one share of common stock.
F3: This note is convertible, at the election of AD Pharma, at any time prior to repayment of the note and matures on July 1, 2023.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Stock Yards Bancorp, Inc.
Report date April 28, 2026 · Filed April 29, 2026
Section 16 reporting ended · disclosed 2026-04-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectTrust Director Deferred Comp Plan | 9,062 |
Reported balance
After 2026-04-28 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-28 · Grant · Acquired 55 · Balance 9,062 F1: Includes shares acquired through automatic dividend reinvestment. |
| Common StockSEC Table I · non-derivative | Direct | 82,940 |
Reported balance
Holding disclosure · report date 2026-04-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 82,940 F2: Restricted Stock Unit cancelled |
| Stock Appreciation RightSEC Table II · derivative / convertible security · Conversion / exercise price $38.85 · Expires 2028-08-28 | Direct | 1,000 |
Reported balance
Holding disclosure · report date 2026-04-28 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares acquired through automatic dividend reinvestment.
F2: Restricted Stock Unit cancelled
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2019 Filed Jun 24, 2019 14:07 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 43.39 | $34.57 | $1,499.99 |
DisclosureSEC source: 0001437749-19-012481 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,155.199 Read SEC document |
| May 23, 2019 Filed May 24, 2019 17:23 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 89.954 | $34.74 | $3,125.00 |
DisclosureSEC source: 0001437749-19-010812 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,111.809 Read SEC document |
| April 30, 2019 Filed May 2, 2019 16:44 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 125.91 | $34.35 | $4,325.01 |
DisclosureSEC source: 0001437749-19-008523 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 1,021.855 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| March 22, 2019 Filed Mar 25, 2019 18:23 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 46.7 | $32.12 | $1,500.00 |
DisclosureSEC source: 0001437749-19-005585 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 889.916 Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 14:05 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 162.864 | $36.38 | $5,924.99 |
DisclosureSEC source: 0001437749-19-003453 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 843.216 Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 16:34 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 150.868 | $33.97 | $5,124.99 |
DisclosureSEC source: 0001437749-19-001310 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 680.352 Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:55 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantCommon Stock | 894 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-19-000206 · rdgdoc.xml · nonDerivative · entry 1 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,304 F2 · price: Restricted stock unit grant with one year vesting. Read SEC document |
| December 21, 2018 Filed Dec 26, 2018 13:53 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 128.646 | $30.51 | $3,924.99 |
DisclosureSEC source: 0001437749-18-022571 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 526.451 Read SEC document |
| November 29, 2018 Filed Nov 30, 2018 16:15 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 126.45 | $31.04 | $3,925.01 |
DisclosureSEC source: 0001437749-18-021400 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 397.805 Read SEC document |
| October 22, 2018 Filed Oct 23, 2018 19:29 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 128.108 | $32.98 | $4,225.00 |
DisclosureSEC source: 0001437749-18-018609 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 271.355 F1 · balance_after: Includes shares acquired through automatic dividend reinvestment. Read SEC document |
| September 20, 2018 Filed Sep 21, 2018 20:45 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 61.828 | $37.20 | $2,300.00 |
DisclosureSEC source: 0001437749-18-017322 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 142.682 Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 15:37 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantStock Appreciation Right · Derivative | 1,000 | $38.85 Strike: $38.85 | $38,850.00 |
DisclosureSEC source: 0001437749-18-016312 · rdgdoc.xml · derivative · entry 4 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-08-28 Read SEC document |
| August 28, 2018 Filed Sep 21, 2018 20:45 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantStock Appreciation Right · Derivative | 1,000 | $38.85 Strike: $38.85 | $38,850.00 |
DisclosureSEC source: 0001437749-18-017322 · rdgdoc.xml · derivative · entry 4 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-08-28 Read SEC document |
| August 28, 2018 Filed Oct 23, 2018 19:29 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | GrantStock Appreciation Right · Derivative | 1,000 | $38.85 Strike: $38.85 | $38,850.00 |
DisclosureSEC source: 0001437749-18-018609 · rdgdoc.xml · derivative · entry 4 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2028-08-28 Read SEC document |
| August 23, 2018 Filed Aug 27, 2018 12:38 UTC | Stock Yards Bancorp, Inc. SYBT · Entity 2761 | PurchaseCommon Stock | 80.854 | $38.65 | $3,125.01 |
DisclosureSEC source: 0001437749-18-016157 · rdgdoc.xml · nonDerivative · entry 3 Schutte John · CIK 0001713580 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Director Deferred Comp Plan Disclosed balance after: 80.854 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.